Menu
← Oncology Approval Tracker
FDA DECISION ·
Enzalutamide (generic Xtandi)
enzalutamide · Actavis Laboratories
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
First generic 40 mg enzalutamide capsules for castration-resistant prostate cancer.
LAMPGEN ANALYSIS
Why it matters
The first generic action applies to a capsule strength and a defined prostate cancer setting.
What research teams should watch
Record capsule strength and formulation and distinguish castration-resistant disease from other label populations.
PRIMARY RECORDS